Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)

J.W. Valle; S. Qin; L. Antonuzzo; D. Tougeron; C-K. Lee; B.J. Tan; M. Ikeda; V. Guthrie; P. McCoon; Y.S. Lee; N. Rokutanda; M. Żotkiewicz; G. Cohen; D-Y. Oh

doi:10.1016/j.annonc.2022.10.104

YUHSpace

BROWSE

0 162

Cited 0 times in

Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)

Authors: J.W. Valle ; S. Qin ; L. Antonuzzo ; D. Tougeron ; C-K. Lee ; B.J. Tan ; M. Ikeda ; V. Guthrie ; P. McCoon ; Y.S. Lee ; N. Rokutanda ; M. Żotkiewicz ; G. Cohen ; D-Y. Oh